Vincere Biosciences Inc
Vincere Biosciences is a Cambridge-based company dedicated to developing disease-modifying therapies for age-related diseases, including Parkinson’s and Kidney disease. The company leverages advanced AI/ML tools and has a strong focus on mitochondrial health and rejuvenation, with a mission to translate scientific findings into innovative treatments and skin care solutions. Backed by top agencies and expert investors, Vincere aims to accelerate the development of its lead USP30 inhibitor program, with the first molecule entering human trials in 2026. The company is committed to open science, continuous learning, and collaboration with leading research institutions and industry partners.
Industries
Nr. of Employees
small (1-50)
Products
Lead USP30 small-molecule inhibitor program
A preclinical small-molecule program targeting a mitochondrial de-ubiquitinating enzyme implicated in mitophagy dysregulation; advanced through discovery and optimization toward IND-enabling studies with planned progression to human trials.
Lead USP30 small-molecule inhibitor program
A preclinical small-molecule program targeting a mitochondrial de-ubiquitinating enzyme implicated in mitophagy dysregulation; advanced through discovery and optimization toward IND-enabling studies with planned progression to human trials.
Services
Computational drug discovery platform and partnership services
Application of a proprietary computational platform combining multi-omics simulation, network analysis, AI/ML, and virtual screening to identify targets, prioritize molecules, and support patient selection; offered via collaborations and research partnerships.
Computational drug discovery platform and partnership services
Application of a proprietary computational platform combining multi-omics simulation, network analysis, AI/ML, and virtual screening to identify targets, prioritize molecules, and support patient selection; offered via collaborations and research partnerships.
Expertise Areas
- Mitophagy-targeted therapeutics
- Parkinson's disease drug development
- Small-molecule inhibitor discovery
- Computational drug discovery and AI/ML
Key Technologies
- AI/ML-driven drug discovery
- Deep neural networks for patient stratification
- Multi-omics simulation
- Large-scale virtual screening